GlobeNewswire

ObsEva announces new composition of its Executive Committee

Share

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, announce today changes to the composition of its Executive Committee following approval by its Board of Directors


Effective today, the following members of ObsEva’s Executive Committee are:


  • Ernest Loumaye, Chief Executive Officer and Co-Founder
  • Tim Adams, Chief Financial Officer
  • Elizabeth Garner, Chief Medical Officer
  • Jean-Pierre Gotteland, Chief Scientific Officer and Head of Research and Development
  • Wim Souverijns, Chief Commercial Officer


Elke Bestel, Vice-President, Head of Drug Safety and Pharmacovigilance, Ben Tan, Vice-President Commercial and Business Development and Fabien de Ladonchamps, Vice-President Corporate Affairs and Finance step down from the Executive Committee with immediate effect, but remain members of the company’s senior management.


Ernest Loumaye, CEO and Co-Founder of ObsEva said: “With the hiring of Wim Souverijns and Elizabeth Garner, the Board believes that it now has an Executive Committee with all the required talents the company needs to steer it through its important upcoming milestones. We would like to warmly thank the talented outgoing members of the management team, for their excellent contribution to the Executive Committee to date”.


About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on The NASDAQ Global Select Market and is trading under the ticker symbol "OBSV", as well as on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”.

For more information, please visit www.ObsEva.com.


Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva’s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva’s product candidates. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, clinical development and related interactions with regulators, ObsEva’s reliance on third parties over which it may not always have full control, and other risks and uncertainties that are described in the Risk Factors section of ObsEva’s Annual Report on Form 20-F for the year ended December 31, 2018, and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva’s website at http://www.obseva.com . Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.


Disclaimer

This is not an offer of securities for sale in the United States. Securities may not be offered or sold in the United States unless they are registered or exempt from registration. Any public offering of securities in the United States, if any, will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management as well as financial statements.

This material does not constitute or contain any offer to sell or invitation to subscribe or make commitments for or in respect of any security in any jurisdiction. There may be restrictions on the distribution of this material in certain jurisdictions, including Canada, Australia, Japan and the member states of the European Economic Area and the United Kingdom of Great Britain and Northern Ireland. Persons into whose possession this material may come are required to inform themselves of and observe any such restrictions.

###

For further information, please contact:


Media Contact Switzerland and Europe:
Christophe Lamps
Dynamics Group
cla@dynamicsgroup.ch
+41 22 308 6220 Office
+41 79 476 26 87 Mobile


Media Contact U.S.:
Marion Janic
RooneyPartners LLC
mjanic@rooneyco.com
+1 212 223 4047 Office
+1 646 537 5649 Mobile


CEO Office Contact:
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550


Investor Contact:
Mario Corso
Senior Director, Investor Relations
mario.corso@obseva.com
+1 857 972 9347 Office
+1 781 366 5726 Mobile


Attachment

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Mandalay Resources Corporation Announces Financial Results for the Second Quarter of 202012.8.2020 23:45:02 CESTPress release

TORONTO, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation ("Mandalay" or the "Company") (TSX: MND, OTCQB: MNDJF) today announced its financial results for the quarter ended June 30, 2020. The Company’s unaudited condensed and consolidated interim financial results for the quarter ended June 30, 2020, together with its Management’s Discussion and Analysis (“MD&A”) for the corresponding period, can be accessed under the Company’s profile on www.sedar.com and on the Company’s website at www.mandalayresources.com. All currency references in this press release are in U.S. dollars except as otherwise indicated. For the second quarter of 2020, the Company generated revenue of $42.3 million, adjusted EBITDA of $21.3 million, and adjusted net income of $7.6 million, or $0.08 income per share. Commenting on the results, Dominic Duffy, President and CEO of Mandalay, noted, “Mandalay’s strong second quarter financial performance was driven by another all-time record in quarterly ad

Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease12.8.2020 22:01:00 CESTPress release

-- Companies to jointly validate novel drug targets -- -- Scipher eligible for upfront, opt-in and milestone payments -- -- Galapagos to progress selected targets into drug discovery -- Mechelen, Belgium and Boston, USA; 12 August 2020 - Galapagos NV (Euronext & Nasdaq: GLPG) and Scipher Medicine (Scipher), a Boston based privately held precision medicine company focused on autoimmune diseases, today announce a collaboration to advance novel drug targets identified by Scipher for the treatment of inflammatory bowel disease (IBD). Scipher combines its proprietary Network Medicine Platform with molecular patient data and AI-based methods to identify novel targets and pathways in autoimmune diseases, including IBD. Scipher and Galapagos will jointly validate a suite of novel IBD targets discovered by Scipher after which Galapagos has the exclusive option to progress up to five targets into further drug discovery and development. Under the terms of the agreement, Scipher is eligible to rec

AND International Publishers NV (ticker: AND.AS) publishes its half year results and trading update12.8.2020 18:05:00 CESTPress release

Capelle aan den IJssel, the Netherlands, 12 August 2020: AND International Publishers NV (ticker: AND.AS) is pleased to share today its half year results and trading update TRADING UPDATE AND HALF YEAR 2020 RESULTS AND grows topline by 22% and reduces net loss by 19% in Covid-19 impacted economic environment. Covid-19 and the related measures taken to prevent the spread of the Corona virus have proved to be a significant challenge for the global economy. The AND team and our underlying business have shown resilience: revenue has increased by 22% compared to the same period in 2019. This is mainly due to our success in winning and delivering new service projects, and moderately growing our existing recurring business. The direct impact of the lockdown was felt most in the data sales segment, where it was difficult to connect with key decision makers and win new customers. OPERATIONAL HIGHLIGHTS AND STRATEGY UPDATE The year began with a good sales pipeline, but the anti-pandemic measures

Volta Finance Limited - Director/PDMR Shareholding12.8.2020 18:03:45 CESTPress release

12 August 2020 VOLTA FINANCE LIMITED (VTA / VTAS) Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons On 12 August 2020, Mr Paul Meader, Director and Chairman of the Board of the Company, transferred 4,495 shares in the Company to his wife, Sarah Kingwell. Following this transaction the total interests in the Company of Mr Meader (and his Closely Associated Persons) remain unchanged at 40,598 shares, representing 0.11% of the issued shares in the Company. The below notification, made in accordance with the requirements of article 19.3 of the EU Market Abuse Regulation, gives further details: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name Paul MeaderSarah Kingwell 2 Reason for the notification a) Position/status Director and Chairman PCA b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platform, auct

Volta Finance Limited : Net Asset Value as at 31 July 202012.8.2020 18:00:00 CESTPress release

Volta Finance Limited (VTA / VTAS) – July 2020 monthly report NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR PART, IN OR INTO THE UNITED STATES ***** Guernsey, 12 August 2020 AXA IM has published the Volta Finance Limited (the “Company” or “Volta Finance” or “Volta”) monthly report for July. The full report is attached to this release and will be available on Volta’s website shortly (www.voltafinance.com). PERFORMANCE and PORTFOLIO ACTIVITY In July the monthly performance, after considering the 11 cents per share dividend paid 29th of July, is negative at -1.2%. Despite a flat performance at the asset class level, USD weakness had a negative impact as USD depreciated against EUR by 4.6% during the month while, after adjusting for hedging, Volta has a USD exposure close to 45%. The monthly asset class performances** were, in local currency: -0.3% for Bank Balance Sheet transactions, +1.1% for CLO Equity tranches; -0.5% for CLO Debt; +5.9% for Cash Corporate Credit deals (this